Objectives: To estimate whether serum somatostatin (SS) and neuron-specific enolase (NSE), the representative neuropeptide relative to learning and memory, to be biochemical markers of the vascular dementia (VaD) in the early stage.
Methods: 42 patients with VaD were randomized in the VaD group and 38 stroke patients without dementia was in the control group. Radioimmunoassay was used to detect SS in the serum and CSF, and Enzyme linked immunosorbent assay to detect NSE in the serum and CSF. SS and NSE in CSF were compared 3 days after stroke. SS and NSE contends in serum were compared 3 days, 3 months and 6 months poststroke.
Results: CSF and serum SS contents in VaD group were lower than that in the control group (P<0.05). SS in the frontal cortex, hippocampus and the temporal lobe, thalamus were lower than that in the occipital lobe (P<0.05); Serum NSE contents in VaD group were significantly higher than that of control group 3 days after stroke, 3 months and 6 months (P<0.01, respectively), and has a tendency to increase (P<0.05); SS contents significantly lower than that in the control group with the trend to decrease (P<0.05).
Conclusions: NSE increased and SS decreased with the lower content in the frontal cortex, hippocampus and the temporal lobe which has close relationship with learning and memory, thus Serum NSE and SS might be the biochemical markers of VaD in the early stage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694494 | PMC |
Publication Analysis
Top Keywords
Similar Publications
[Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors.
EJNMMI Radiopharm Chem
December 2024
Department of Nuclear Engineering, University of Tennessee, Knoxville, Knoxville, TN, 37996, USA.
Background: Neuroendocrine tumors (NETs) are clinically diverse types of tumors that can arise anywhere in the body. Previous studies have shown that somatostatin receptors (SSTRs) are overexpressed on NET cell membranes relative to healthy tissue, allowing for tumor targeting through radiolabeled somatostatin analogs (SSAs). This work aims to develop a novel Zr-labeled tracer incorporating the SSA, octreotide (TOC), for positron emission tomography (PET) imaging of SSTR + NETs and predictive dosimetry calculations, leveraging the excellent nuclear (t = 3.
View Article and Find Full Text PDFXuebijing and somatostatin against acute pancreatitis: A systematic review and network pharmacology.
Medicine (Baltimore)
December 2024
Department of Pharmacy, Affiliated Hospital 2 of Nantong University, And First People's Hospital of Nantong City, Nantong, Jiangsu Province, P.R. China.
Background: Acute pancreatitis (AP) is a common pancreatic disease. Xuebijing injection (XBJ) combined with somatostatin in the treatment of AP is frequently used in clinical practice. There is, however, a lack of high-quality evidence-based evidence and network pharmacology to regard the therapeutic efficacy and pharmacological mechanisms.
View Article and Find Full Text PDFCushing's Disease Manifestation in -Mutated Corticotropinoma May Be Mediated by Interactions Between WNT Signaling and SST Trafficking.
Int J Mol Sci
November 2024
Almazov National Medical Research Centre, 197341 Saint Petersburg, Russia.
In the current work, we aimed to evaluate the association of clinical data of Cushing's disease (CD) patients with mutation status and to study USP8-related molecular mechanisms connected to the regulation of corticotropinoma growth and activity. 35 CD patients were enrolled; the sequencing of exon 14 in revealed variants in eighteen adenomas, two of which were described for the first time in CD. variants were more common in women (94% vs.
View Article and Find Full Text PDFSomatostatin Receptor Imaging in the Diagnosis and Management of Parathyroid Neuroendocrine Neoplasia.
Diagnostics (Basel)
December 2024
Almazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Background: Parathyroid tumors are classified as parathyroid neuroendocrine neoplasia (NEN) by the IARC-WHO classification. These tumors can occur with NENs from other sites, which often require total-body [68Ga]-DOTA-peptides PET/CT. This study aimed to assess the utility of [68Ga]-DOTA-peptide PET/CT in imaging parathyroid NENs and to evaluate the underlying mechanisms.
View Article and Find Full Text PDFChallenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.
J Neuroendocrinol
December 2024
Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Assessing the response to systemic therapy in neuroendocrine tumors (NET) is challenging since morphological imaging response is often delayed and not necessarily reflective of clinical benefit. Peptide receptor radionuclide therapy (PRRT) has a complex mechanism of action, further complicating response assessment. In response to these challenges, the European Neuroendocrine Tumor Society (ENETS) Theranostics Task Force conducted a statement-based survey among experts to identify the current landscape and unmet needs in PRRT response assessment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!